(Riboflavin + sodium iodide) is under clinical development by Epion Therapeutics and currently in Phase III for Keratoconus. According to GlobalData, Phase III drugs for Keratoconus does not have sufficient historical data to build an indication benchmark PTSR for Phase III. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Riboflavin + sodium iodide) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Riboflavin + sodium iodide) overview

A fixed-combination of riboflavin and sodium iodide (CXL-005) is under development for the treatment of keratoconus, forme fruste keratoconus, post-LASIK ectasia, pellucid marginal degeneration, forme fruste pellucid marginal degeneration, and Terrine's marginal degeneration. It is a transepithelial (epi-on) corneal cross-linking (CXL) therapy developed based on EpiSmart system. It is administered as ophthalmic solution.

Epion Therapeutics overview

Epion Therapeutics focused on research and developing of minimally?invasive treatments for ectatic corneal disease including keratoconus. The company is headquartered in Burlington, Massachusetts, the US.

For a complete picture of (Riboflavin + sodium iodide)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 22 April 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.